Short Interest in Immatics (NASDAQ:IMTX) Grows By 6.2%

Immatics (NASDAQ:IMTX) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 8,910,000 shares, an increase of 6.2% from the March 15th total of 8,390,000 shares. Based on an average daily trading volume, of 526,500 shares, the days-to-cover ratio is presently 16.9 days.

Immatics Stock Down 2.0 %

Shares of IMTX stock opened at $10.40 on Tuesday. The firm has a 50 day moving average of $11.55 and a 200-day moving average of $10.45. The company has a market cap of $880.46 million, a price-to-earnings ratio of -8.00 and a beta of 0.67. Immatics has a 52 week low of $6.31 and a 52 week high of $13.16.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Immatics had a negative net margin of 179.67% and a negative return on equity of 43.58%. The business had revenue of $17.14 million during the quarter, compared to analysts’ expectations of $11.78 million. Analysts anticipate that Immatics will post -1.44 earnings per share for the current year.

Institutional Trading of Immatics

Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in Immatics by 13.3% during the 4th quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after buying an additional 747,772 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Immatics by 324.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock valued at $16,310,000 after acquiring an additional 1,183,860 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Immatics by 44.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,334,169 shares of the company’s stock worth $24,579,000 after purchasing an additional 719,634 shares during the period. Exome Asset Management LLC bought a new position in shares of Immatics in the 4th quarter worth $1,368,000. Finally, Virtus ETF Advisers LLC lifted its holdings in shares of Immatics by 14.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,447 shares of the company’s stock worth $99,000 after purchasing an additional 1,184 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.